At Aeroimmune Inc., we are a dedicated team of clinicians and scientists with decades of expertise in mucosal immunity and vaccine development.

​

We are an innovative biotechnology company focused on developing next-generation vaccines that target respiratory pathogens directly at the site of infection. Our groundbreaking technology utilizes recombinant adenoviruses to deliver vaccine antigens directly to the airways, stimulating robust and localized immune responses.

​

We believe our targeted approach to mucosal immunization offers superior protection against respiratory diseases. By focusing the immune response where pathogens enter the body, we aim to revolutionize vaccine efficacy and safety.

​

​

​

We aim to set a new standard in respiratory immunization, offering a more precise and effective way to protect against a range of respiratory illnesses, with the potential to transform global health.